"EST-P-EXO1" aims to regenerate damaged cartilage tissue and suppress pain
Bio-venture Exostemtech has applied for the domestic clinical trial plan (IND) for the first time in Korea.
Exostemtech, a company specializing in developing exosome-based treatments, announced on the 21st that it has applied for a clinical trial plan (IND) to the Ministry of Food and Drug Safety to proceed with phase 1 clinical trials in Korea for osteoarthritis treatment candidate "EST-P-EXO1" (CARTISOME®).
In this phase 1, Exostemtech evaluates the safety of EST-P-EXO1 in patients with knee osteoarthritis. This clinical trial will be conducted at the Catholic University of Korea Uijeongbu St. Mary's Hospital for up to 28 patients.